Ginkgo Bioworks Reports Revenue Decline and Increased Net Loss in Q2 2026

Ginkgo Bioworks Holdings, Inc. reported a significant decline in financial performance for the second quarter of 2026, with revenues of $20.2 million, down from $39.1 million in the same period last year. For the first half of 2026, total revenue was $39.6 million, compared to $77.4 million in the first half of 2025. The decrease in revenue was attributed to reduced service scope for a major customer in the agriculture sector and a decline in programs with large enterprise clients in the pharmaceutical and biotechnology industries. The company also recognized a decrease in non-cash revenue from prior contracts, which contributed to the overall decline.

Operating expenses for the second quarter were $78.7 million, a reduction from $97.3 million in the prior year, primarily due to lower research and development costs, which fell to $46.2 million from $53.4 million. General and administrative expenses also decreased to $30.8 million from $35.0 million. The company did not incur any restructuring charges in the latest quarter, contrasting with $3.6 million in the same period last year. Despite these reductions, Ginkgo reported a net loss from continuing operations of $57.3 million for the quarter, compared to a loss of $53.2 million in the previous year.

In terms of strategic developments, Ginkgo completed the divestiture of its Biosecurity business on April 3, 2026, which has been classified as discontinued operations. This divestiture resulted in a gain of $24.5 million recognized in the second quarter. The company now retains a minority equity interest in Perimeter Systems, Inc., the purchaser of the Biosecurity business, which is accounted for using the equity method. This strategic shift is expected to impact Ginkgo's operational focus and financial results moving forward.

Operationally, Ginkgo's total assets decreased to $990.0 million as of June 30, 2026, down from $1.1 billion at the end of 2025. The company reported cash and cash equivalents of $84.5 million, a significant decline from $167.2 million at the end of the previous year. The company’s employee headcount has also been reduced as part of its restructuring efforts, which began in 2024 and aimed to streamline operations and reduce costs. Ginkgo's management indicated that they expect to stabilize operational overhead and continue to prioritize investments in their tools offerings.

Looking ahead, Ginkgo Bioworks anticipates that its expenditures will exceed revenues for at least the next 12 months as it continues to invest in research and development and expand its service offerings. The company has sufficient liquidity, with cash and marketable securities totaling $302.2 million as of June 30, 2026, which it believes will support its operations through the next year. Ginkgo's management remains focused on enhancing its cell engineering platform and expects to see improvements in operational efficiency and revenue generation as it implements its strategic initiatives.